Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Altimmune, Inc.

Market Cap 570M 499M 461M 430M 807M 53.94B 814M 5.48B 2.13B 26.47B 2.14B 2.09B 92.06B P/E 2026 *
-4.35x
P/E 2027 * -3.87x
Enterprise Value 187M 163M 151M 141M 264M 17.68B 267M 1.8B 698M 8.68B 701M 686M 30.18B EV / Sales 2026 *
45,555x
EV / Sales 2027 * -
Free-Float
99.59%
Yield 2026 *
-
Yield 2027 * -
1 day+8.52%
1 week+12.26%
Current month-3.93%
3 months-12.28%
6 months-24.87%
Current year-18.84%
1 week 2.6
Extreme 2.6
3.04
1 month 2.57
Extreme 2.5702
3.13
Current year 2.56
Extreme 2.56
6.44
1 year 2.56
Extreme 2.56
7.73
3 years 2.09
Extreme 2.09
14.84
5 years 2.09
Extreme 2.09
23.49
10 years 1.51
Extreme 1.51
237.3
Manager TitleAgeSince
Chief Executive Officer 58 2025-12-31
Director of Finance/CFO 70 2024-11-10
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 78 2017-12-31
Director/Board Member 74 2004-07-31
Director/Board Member 58 2003-08-31
Date Insider Type Main position Quantity % Market Cap.
04-30Free

Director

48,800 0.0251%
04-30Free

Director

48,800 0.0251%
04-30Free

Director

48,800 0.0251%
Change 5-day change 1-year change 3-year change Capi.($)
+8.52%+12.26%-58.32%-30.07% 525M
+2.87%+1.58%+68.97%+122.28% 55.19B
+4.00%+7.14%+63.67%+68.77% 45.75B
-0.77%-0.39%-15.34%-16.07% 22.98B
+2.93%+0.77%-3.97%+376.58% 20.76B
-0.26%-1.09%+27.55%-18.57% 16.26B
+1.16%+2.25%+20.23%-35.78% 15.42B
-1.08%-3.35%+27.20%+170.12% 13.05B
+3.30%+15.38%+133.24%+273.89% 12.45B
-5.63%-5.49%+21.79% - 12.37B
Average +1.50%+3.26%+28.50%+101.24% 21.48B
Weighted average by Cap. +1.68%+2.66%+43.29%+109.22%

Financials

2026 *2027 *
Net sales 4.1K 3.59K 3.32K 3.09K 5.8K 388K 5.86K 39.43K 15.32K 190K 15.39K 15.06K 662K -
Net income -112M -97.83M -90.41M -84.38M -158M -10.58B -160M -1.08B -418M -5.19B -420M -411M -18.06B -139M -122M -113M -105M -197M -13.18B -199M -1.34B -520M -6.47B -523M -511M -22.49B
Net Debt -383M -335M -310M -289M -542M -36.26B -547M -3.68B -1.43B -17.79B -1.44B -1.41B -61.88B -256M -224M -207M -193M -362M -24.23B -366M -2.46B -956M -11.89B -961M -940M -41.35B
Logo Altimmune, Inc.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Employees
57
Date Price Change Volume
26-06-22 2.930 $ +8.52% 5,759,810
26-06-18 2.700 $ +2.27% 11,688,234
26-06-17 2.640 $ +0.76% 3,570,898
26-06-16 2.620 $ -0.76% 2,907,175
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
2.700USD
Average target price
15.45USD
Spread / Average Target
+472.22%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!